CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 30 enrolled
Drug / intervention
Radioiodine +1 moreradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01039818
NCT01039818Phase 3Completed
CompareCT.gov

Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism: A Clinical Trial With Historical Control

Hospital de Clinicas de Porto Alegre·interventional·Posted Dec 25, 2009·Updated Sep 6, 2012

In Brief

A Phase 3 clinical trial evaluating Radioiodine for Graves Disease. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether higher doses of radioiodine increase treatment efficacy in severe Graves' disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGraves Disease
CountriesBrazil
CollaboratorsFederal University of Rio Grande do Sul

Timeline

Phase 3CompletedFinished
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 25, 2009
Enrollment StartFeb 1, 1997
Primary CompletionAug 1, 2011
TodayJul 2, 2026
Enrollment to primary: 14.5 yearsPosted 16.5 years ago

Interventions

Radioiodineradiation

A unique dose of 200µCi of ¹³¹I/ml/24-RAIU

Radioiodineradiation

A unique dose of 250µCi of ¹³¹I/ml/24-RAIU